Emerging research suggest Retatrutide , a dual activator targeting both incretin and GIP , may offer a notable development for weight loss . Early human trials have shown substantial reductions in abdominal mass , conceivably surpassing current body composition medications . Despite this, additional study is necessary to thoroughly assess its lasti